ARL14EP

Summary

ARL14EP (ARF like GTPase 14 effector protein, HGNC:26798) is a protein-coding gene on chromosome 11p14.1, encoding ARL14 effector protein (Q8N8R7). Through its interaction with ARL14 and MYO1E, may connect MHC class II-containing cytoplasmic vesicles to the actin network and hence controls the movement of these vesicles along the actin cytoskeleton in dendritic cells.

The protein encoded by this gene is an effector protein. It interacts with ADP-ribosylation factor-like 14 [ARL14, also known as ADP-ribosylation factor 7 (ARF7)], beta-actin (ACTB) and actin-based motor protein myosin 1E (MYO1E). ARL14 is a small GTPase; it controls the export of major histocompatibility class II molecules by connecting to the actin network via this effector protein.

Source: NCBI Gene 120534 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 10
• Clinical variants (ClinVar): 42 total — 2 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_152316

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26798
Approved symbol	ARL14EP
Name	ARF like GTPase 14 effector protein
Location	11p14.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38968, ARF7EP
Ensembl gene	ENSG00000152219
Ensembl biotype	protein_coding
OMIM	612295
Entrez	120534

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000282032, ENST00000530909, ENST00000532047, ENST00000533457, ENST00000862264, ENST00000862265, ENST00000918202, ENST00000918203

RefSeq mRNA: 1 — MANE Select: NM_152316 NM_152316

CCDS: CCDS7869

Canonical transcript exons

ENST00000282032 — 4 exons

Exon	Start	End
ENSE00001004037	30330886	30331374
ENSE00001217522	30332866	30332993
ENSE00001400052	30336567	30338223
ENSE00002177420	30323104	30323202

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 97.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.6786 / max 244.0114, expressed in 1792 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
113583	17.6337	1775
113584	2.3831	1269
113582	0.3785	179
113585	0.2832	88

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.16	gold quality
oocyte	CL:0000023	96.91	gold quality
calcaneal tendon	UBERON:0003701	94.60	gold quality
adrenal tissue	UBERON:0018303	93.24	gold quality
smooth muscle tissue	UBERON:0001135	92.19	gold quality
embryo	UBERON:0000922	91.19	gold quality
ganglionic eminence	UBERON:0004023	91.19	gold quality
islet of Langerhans	UBERON:0000006	91.16	gold quality
cortical plate	UBERON:0005343	91.05	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.52	gold quality
gall bladder	UBERON:0002110	90.19	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.05	gold quality
tendon	UBERON:0000043	90.04	gold quality
leukocyte	CL:0000738	89.91	gold quality
endothelial cell	CL:0000115	89.90	gold quality
monocyte	CL:0000576	89.84	gold quality
right adrenal gland cortex	UBERON:0035827	89.74	gold quality
lymph node	UBERON:0000029	89.68	gold quality
right adrenal gland	UBERON:0001233	89.67	gold quality
Brodmann (1909) area 9	UBERON:0013540	89.47	gold quality
vermiform appendix	UBERON:0001154	89.43	gold quality
left ovary	UBERON:0002119	89.40	gold quality
left adrenal gland	UBERON:0001234	89.35	gold quality
left adrenal gland cortex	UBERON:0035825	89.29	gold quality
muscle of leg	UBERON:0001383	89.17	gold quality
adrenal gland	UBERON:0002369	89.01	gold quality
descending thoracic aorta	UBERON:0002345	88.93	gold quality
epithelial cell of pancreas	CL:0000083	88.90	silver quality
gastrocnemius	UBERON:0001388	88.88	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.67	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting ARL14EP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-548AC	99.84	70.77	4351

Literature-anchored findings (GeneRIF, showing 3)

• RNA-guided epigenetic editing of Sema6a gene promoters via a dCas9-SunTag system with C11orf46 binding normalized SEMA6A expression and rescued transcallosal dysconnectivity via repressive chromatin remodeling by the SETDB1 repressor complex. (PMID:31511512)
• Transcriptome-wide association analyses identify an association between ARL14EP and polycystic ovary syndrome. (PMID:36720993)
• Structural evidence for protein-protein interaction between the non-canonical methyl-CpG-binding domain of SETDB proteins and C11orf46. (PMID:38159574)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	arl14ep	ENSDARG00000001210
mus_musculus	Arl14ep	ENSMUSG00000027122
rattus_norvegicus	Arl14ep	ENSRNOG00000004891

Paralogs (7): THAP3 (ENSG00000041988), THAP1 (ENSG00000131931), THAP8 (ENSG00000161277), THAP2 (ENSG00000173451), THAP6 (ENSG00000174796), THAP7 (ENSG00000184436), ARL14EPL (ENSG00000268223)

Protein

Protein identifiers

ARL14 effector protein — Q8N8R7 (reviewed: Q8N8R7)

Alternative names: ARF7 effector protein

All UniProt accessions (2): Q8N8R7, E9PRK7

UniProt curated annotations — full annotation on UniProt →

Function. Through its interaction with ARL14 and MYO1E, may connect MHC class II-containing cytoplasmic vesicles to the actin network and hence controls the movement of these vesicles along the actin cytoskeleton in dendritic cells.

Subunit / interactions. Interacts with ARL14 and MYO1E.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in the immune system.

RefSeq proteins (1): NP_689529* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029264	ARF7EP_C	Domain

Pfam: PF14949

UniProt features (12 total): strand 2, modified residue 2, sequence conflict 2, turn 2, chain 1, region of interest 1, cross-link 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8HFP	X-RAY DIFFRACTION	1.82

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N8R7-F1	80.81	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 1, 183, 177

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 105 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN, AACTTT_UNKNOWN, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, DELASERNA_MYOD_TARGETS_DN, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, BERENJENO_TRANSFORMED_BY_RHOA_UP, GOCC_ANCHORING_JUNCTION, P53_02, chr11p14, ATF5_TARGET_GENES, ATF6_TARGET_GENES, CBX7_TARGET_GENES, CHAF1B_TARGET_GENES, HMG20B_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), plasma membrane (GO:0005886), focal adhesion (GO:0005925), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
nuclear lumen	2
binding	1
intracellular membraneless organelle	1
cytoplasm	1
membrane	1
cell periphery	1
cell-substrate junction	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

928 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL14EP	ARL14	Q8N4G2	731
ARL14EP	SETDB1	Q15047	669
ARL14EP	SETDB2	Q96T68	659
ARL14EP	ATF7IP	Q6VMQ6	575
ARL14EP	MYO1E	Q12965	558
ARL14EP	SUOX	P51687	504
ARL14EP	DNAJC24	Q6P3W2	503
ARL14EP	TCP11L1	Q9NUJ3	475
ARL14EP	FSHB	P01225	474
ARL14EP	OSCP1	Q8WVF1	466
ARL14EP	PLGRKT	Q9HBL7	463
ARL14EP	PDRG1	Q9NUG6	449
ARL14EP	ADGRE3	Q9BY15	447
ARL14EP	ZNF526	Q8TF50	444
ARL14EP	NAA50	Q9GZZ1	440

IntAct

46 interactions, top by confidence:

A	B	Type	Score
ARL14EP	SETDB2	psi-mi:“MI:0915”(physical association)	0.740
BRK1	HSBP1	psi-mi:“MI:0914”(association)	0.740
ARL14EP	SETDB2	psi-mi:“MI:0915”(physical association)	0.670
FAF2	UBB	psi-mi:“MI:0914”(association)	0.640
KANK2	ARL14EP	psi-mi:“MI:0915”(physical association)	0.560
ATF7IP	ARL14EP	psi-mi:“MI:0915”(physical association)	0.560
ARL14EP	ARL14	psi-mi:“MI:0915”(physical association)	0.540
ARL14	ARL14EP	psi-mi:“MI:0403”(colocalization)	0.540
MAGEA1	MAGEB3	psi-mi:“MI:0914”(association)	0.530
ARL14EP	MYO1E	psi-mi:“MI:0915”(physical association)	0.520
MYO1E	ARL14EP	psi-mi:“MI:0915”(physical association)	0.520
Setdb1	INPP5B	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
PNKD	EXOC5	psi-mi:“MI:0914”(association)	0.350
SETDB2	DHX16	psi-mi:“MI:0914”(association)	0.350
ATF7IP	IGHG2	psi-mi:“MI:0914”(association)	0.350
VHL	UTRN	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POM121C	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POTEF	psi-mi:“MI:0914”(association)	0.350
ARL14EP	ARPC2	psi-mi:“MI:0914”(association)	0.350
RNF4	KPNA3	psi-mi:“MI:0914”(association)	0.350
HSF2BP	PRC1	psi-mi:“MI:0914”(association)	0.350
BRK1	KIF5C	psi-mi:“MI:0914”(association)	0.350

BioGRID (42): ARL14EP (Two-hybrid), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), PLEKHF2 (Two-hybrid), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS), ARL14EP (Two-hybrid), KANK2 (Two-hybrid), ARL14EP (Affinity Capture-MS), ARL14EP (Affinity Capture-MS)

ESM2 similar proteins: A0A345BJN7, A0A7H0DN82, B6EU02, O13033, O45595, O93182, P03347, P03348, P03975, P04592, P04593, P05887, P05890, P05892, P0C798, P0C799, P0DP91, P12450, P12495, P13784, P18800, P19199, P27978, P34470, P35962, P40083, P40847, P69730, P69731, P69732, Q02271, Q23243, Q28C26, Q2HEW5, Q54CZ6, Q5EA92, Q5FVK8, Q67708, Q6DRC3, Q6EWG9

Diamond homologs: P0DKL9, Q3UKZ7, Q5EA92, Q5FVK8, Q8BIX3, Q8N8R7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	28
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3777757	Single allele	Pathogenic
563875	GRCh37/hg19 11p14.1-13(chr11:29883001-33865721)x1	Pathogenic
183284	NM_152316.3(ARL14EP):c.653G>A (p.Gly218Glu)	Likely pathogenic

SpliceAI

822 predictions. Top by Δscore:

Variant	Effect	Δscore
11:30323198:C:G	donor_gain	1.0000
11:30332864:A:AG	acceptor_gain	1.0000
11:30332864:AG:A	acceptor_gain	1.0000
11:30332865:G:GG	acceptor_gain	1.0000
11:30332865:GG:G	acceptor_gain	1.0000
11:30332865:GGGAA:G	acceptor_gain	1.0000
11:30332989:GACAG:G	donor_gain	1.0000
11:30332990:ACAG:A	donor_loss	1.0000
11:30332991:CAG:C	donor_loss	1.0000
11:30332992:AGGT:A	donor_loss	1.0000
11:30332993:GG:G	donor_loss	1.0000
11:30332994:G:T	donor_loss	1.0000
11:30332995:T:C	donor_loss	1.0000
11:30336566:GACAA:G	acceptor_gain	1.0000
11:30323188:A:T	donor_gain	0.9900
11:30323197:GC:G	donor_gain	0.9900
11:30331372:GAT:G	donor_gain	0.9900
11:30331375:G:GG	donor_gain	0.9900
11:30332860:CTTCA:C	acceptor_loss	0.9900
11:30332861:TTCA:T	acceptor_loss	0.9900
11:30332864:A:AT	acceptor_loss	0.9900
11:30332865:G:A	acceptor_loss	0.9900
11:30332998:GC:G	donor_gain	0.9900
11:30336561:TTACA:T	acceptor_loss	0.9900
11:30336562:TACA:T	acceptor_loss	0.9900
11:30336563:ACAG:A	acceptor_loss	0.9900
11:30336565:A:AC	acceptor_loss	0.9900
11:30336565:A:AG	acceptor_gain	0.9900
11:30336566:G:GG	acceptor_gain	0.9900
11:30336566:G:GT	acceptor_loss	0.9900

AlphaMissense

1718 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:30336637:T:C	C209R	1.000
11:30336643:T:C	C211R	1.000
11:30336727:C:A	R239S	1.000
11:30336733:T:A	W241R	1.000
11:30336733:T:C	W241R	1.000
11:30336735:G:C	W241C	1.000
11:30336735:G:T	W241C	1.000
11:30330961:T:C	C5R	0.999
11:30330997:T:C	C17R	0.999
11:30331082:G:C	R45T	0.999
11:30331083:A:C	R45S	0.999
11:30331083:A:T	R45S	0.999
11:30331117:T:C	C57R	0.999
11:30331119:C:G	C57W	0.999
11:30331171:T:C	C75R	0.999
11:30331240:G:C	A98P	0.999
11:30331294:T:C	C116R	0.999
11:30331303:T:A	C119S	0.999
11:30331303:T:C	C119R	0.999
11:30331304:G:C	C119S	0.999
11:30336607:G:C	G199R	0.999
11:30336637:T:A	C209S	0.999
11:30336638:G:A	C209Y	0.999
11:30336638:G:C	C209S	0.999
11:30336638:G:T	C209F	0.999
11:30336639:T:G	C209W	0.999
11:30336641:A:T	D210V	0.999
11:30336643:T:A	C211S	0.999
11:30336644:G:A	C211Y	0.999
11:30336644:G:C	C211S	0.999

dbSNP variants (sampled 300 via entrez): RS1000009799 (11:30338353 G>C), RS1000273552 (11:30323590 T>G), RS1000306076 (11:30323374 C>A,T), RS1000380091 (11:30323209 G>A,C), RS1000581550 (11:30336429 G>T), RS1000895010 (11:30329907 A>G), RS1000993227 (11:30336863 T>C), RS1001730938 (11:30333104 A>C,G), RS1001779988 (11:30323772 G>A), RS1001793205 (11:30333718 A>G), RS1001866702 (11:30333375 A>G), RS1001979122 (11:30326860 G>T), RS1002400389 (11:30330318 A>G), RS1002641694 (11:30329744 T>C), RS1002756090 (11:30323455 C>T)

Disease associations

OMIM: gene MIM:612295 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (2): microcephaly (MONDO:0001149), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST005273_5	Polycystic ovary syndrome	2.000000e-08
GCST006291_10	Spherical equivalent or myopia (age of diagnosis)	2.000000e-08
GCST006624_54	Systolic blood pressure	6.000000e-13
GCST006979_786	Heel bone mineral density	6.000000e-16
GCST007089_8	Polycystic ovary syndrome	9.000000e-13
GCST007565_37	Morning person	2.000000e-14
GCST007576_84	Chronotype	2.000000e-14
GCST010002_234	Refractive error	2.000000e-49
GCST010988_412	Adult body size	1.000000e-13
GCST90000050_50	Age at first birth	3.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004847	age at onset
EFO:0006335	systolic blood pressure
EFO:0009270	heel bone mineral density
EFO:0008328	chronotype measurement
EFO:0009101	age at first birth measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Diethylstilbestrol	increases expression	1
Folic Acid	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Polychlorinated Biphenyls	affects expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Tretinoin	decreases expression	1
Zinc	decreases expression	1
Aflatoxin B1	decreases methylation	1
Aflatoxin M1	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

219 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice